Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Gipfel Life Sciences Gmbh

Clinical trials sponsored by Gipfel Life Sciences Gmbh, explained in plain language.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

New drug combo targets ALS inflammation in genetically selected patients Results expected Jun 2027 (estimated)

Browse trials soon ready across all sponsors →

Not yet recruiting 1

New drug combo targets ALS inflammation in genetically selected patients

Disease control Not yet recruiting

This study tests whether combining two drugs (galunisertib and nerandomilast) can slow the progression of ALS in 60 people who have high levels of a protein called GREM2. The drugs aim to reduce brain inflammation and nerve cell damage. Participants will receive either the drug c…

Phase 2/3 • Sponsor: Gipfel Life Sciences GmbH • Aim: Disease control

Last updated Jun 27, 2026 08:08 UTC